GTX-102 for Angelman syndrome Feasibility Questionnaire

Dr. Aneal Khan at MAGIC Clinic Ltd. in Calgary is considering a study in patients with Angelman syndrome using an investigational (research) drug called GTX-102.

The study has not yet been approved in Calgary and right now we are trying to determine how many patients may be interested and whether Calgary should be a site for the study. Dr. Khan is conducting a feasibility questionnaire to see how many patients may be eligible - the information is anonymous and will not identify anyone. We simply want a rough idea of eligible patients. Formal determination of eligibility will only take place after ethics approval is complete and we can proceed with enrolment. Answering the questionnaire does not place you on a waiting list for the study nor put you in cue to be contacted if the study starts.

We do not collect any personal identifying information or contact information.

You will find other sites for this study listed at the following website:

https://www.clinicaltrials.gov/ct2/show/NCT04259281?term=gtx-102&draw=2&rank=1